1 / 48

Treating the outpatient with severe IBD: Case studies

Treating the outpatient with severe IBD: Case studies. Daniel H. Present, MD, MACG Clinical Professor of Medicine The Mount Sinai School of Medicine Russell D. Cohen, MD, FACG , AGAF Professor of Medicine, Pritzker Medical School Co-Director, Inflammatory Bowel Disease Center

marlis
Télécharger la présentation

Treating the outpatient with severe IBD: Case studies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treating the outpatient with severe IBD: Case studies Daniel H. Present, MD, MACG Clinical Professor of Medicine The Mount Sinai School of Medicine Russell D. Cohen, MD, FACG, AGAF Professor of Medicine, Pritzker Medical School Co-Director, Inflammatory Bowel Disease Center The University of Chicago Medical Center

  2. Case 1 : Severe Ulcerative Colitis • Russ Cohen

  3. New Patient Visit • 24 yo Black female • Moved to Chicago from Maryland to pursue career at Boeing. • 1 month ago: developed painless BRBPR with mucus: • Flexible sigmoidoscopy to 60cm: 10cm of proctitis; normal proximal. Biopsies of the affected area revealed active proctitis, crypt abscesses, not much chronicity. Proximal biopsies were normal.

  4. What Would YOU Do? • Any additional workup at this time? • Full colonoscopy? • Small bowel imaging? • Upper endoscopy? • Therapeutic Options: • Mesalamine 1g suppositories qhs? • Mesalamine 4g enemas qhs? • Topical steroids instead? • Oral 5-ASA? • Oral steroids?

  5. Initial Clinical Course • Starts 5-ASA suppositories • Initially attains remission • Stops suppositories, relapses. • Restart suppositories – not responding, now worse. • 5 to 6 blood bowel movements, cramping, diarrhea

  6. What Would YOU Do? • Restart 5-ASA 1g suppository; see how she does. • Start 5-ASA enema? • Start oral 5-ASA? • Start oral steroids? • Check stool specs. • Start nothing; set up for scope

  7. Your Decision… • She underwent flexible sigmoidoscopy (unprepped) in your office: • Limited to 40cm • Showed moderately active UC to 30cm with an abrupt cut-off to normal mucosa L Colon: Sharp demarcation line Rectum: Circumferential, Continuous Inflammation

  8. Next Steps: • Mesalamine enemas started; patient can’t hold them. • Oral mesalamine 4.8g started; patient seemed to worsen. • Oral prednisone (20mg po bid) started; patient still without obvious improvement.

  9. Why Aren’t the Steroids Working? • ? Too sick • ? Infected (ie. C diff) • ? Wrong Diagnosis • They are working for his colitis; diarrhea is of other origin. • Celiac? • 5-ASA diarrhea? • IBS? • Dietary

  10. Typically Abrupt Onset. Often can identify a “trigger”: Infection, antibiotic, major life stress “Get Over” the acute insult. Often Early in Disease Course: 10% of fulminant colitics – initial presentation. Median Age  early- mid 30’s Disease Duration: median 4-7 years Acute, Severe Colitis…. Cohen RD et al. Am J Gastroenterol 1999;94:1587-92. Stack WA et al. Aliment Pharmacol Ther 1998;12:973-8 Wenzl HH et al. Z Gastroenterol 1998;36:287-93. D’Haens G et al. Gastroenterology 2001;120:1323-9 Hyde GM et al. Eur J Gastroenterol Hepatol 1998;10:411-3.

  11. Options for Severe Colitis • If responsive to oral steroids: • Immunomodulators (aza, 6MP) with gradual taper of steroids • Infliximab • Adalimumab

  12. Azathioprine or 6-MP in UC 80% 70% 60% 50% 40% 30% 20% 10% 0% Maintenance of Remission in UC Steroid-Dependent Active UC 90% AZA AZA/6-MP 80% Placebo Placebo 70% 60% Response Rate 50% Relapse Rate 40% 30% 20% 10% 0% 2.0 mg/kg/d3 2.2mg/k/d4 100 mg/d2 1.5-2.0 mg/kg/d1 100 mg/d2 AZA:azathioprine. 6-MP: 6-mercaptopurine 1)Jewell DP, Truelove SC. Br Med J. 1974;4:627-630. 2)Hawthorne AB, et al. Br Med J. 1992;305:20-22. 3)Ardizzone S, et al. Gut. 2006;55:47-53. 4)Mantzaris et al. Am J Gastroenterol. 2004;99:1122-1128.

  13. 6-MP Maintenance in UC UC – Maintenance Therapy n=83 1.0 .8 .6 .4 .2 0 Probability of Remission Maintenance 0 20 40 60 Months George J et al. Amer J Gastroenterol 1996; 91:1711

  14. Infliximab in UC: Clinical Remission ACT 1 ACT 2 ‡ † ‡ † † † ‡ ‡ †P.002 vs placebo‡P.003 vs placebo Rutgeerts P et al. N Engl J Med. 2005;353:2462-2476.

  15. Infliximab in UC: Mucosal Healing ACT 1 ACT 2 ‡ † ‡ † ‡ † † ‡ Mucosal healing = endoscopic subscore of 0 or 1 †P<.001 vs placebo‡P.009 vs placebo Rutgeerts P et al. N Engl J Med. 2005;353:2462-2476.

  16. Infliximab in UC Corticosteroid Discontinuation at Week 30 ACT 1 ACT 2 ‡ † ‡ †P=.030 vs placebo‡P.010 vs placebo Rutgeerts P et al. N Engl J Med. 2005;353:2462-2476.

  17. Infliximab, Azathioprine, or Infliximab + Azathioprine for the Treatment of Moderate to Severe Ulcerative Colitis:“UC SUCCESS Trial” Randomization of Patients AZA + PBO (2.5 mg/kg) (n=79) IFX (5 mg/kg) + PBO (n=78) IFX+AZA(n=80) Visits Week 0 Week 2 Week 6 Possible escape* (blinded) Week 8 Week 14 Primary Evaluation Week 16 *Subjects not achieving ≥1 point improvement in partial Mayo score Infusions ABSTRACT ONLY Panaccione et al. DDW 2011 Abstract #835

  18. Infliximab, Azathioprine, or Infliximab + Azathioprine for the Treatment of Moderate to Severe Ulcerative Colitis:“UC SUCCESS Trial” P = 0.032 vs. AZA P = 0.017 vs. IFX * Total Mayo score < 2, no subscore >1, no steroids. ABSTRACT ONLY Panaccione et al. DDW 2011 Abstract #835

  19. Co-administration of Immunosuppressants: Dramatically Lower anti-Infliximab antibody rates • “SONIC” Crohn’s Disease Trial: • Infliximab alone: 14% anti-Infix antibodies • Infliximab + Aza: 1%anti-Infix antibodies • “UC-Success” Ulcerative Colitis Trial: • Infliximab alone: 14% anti-Infix antibodies • Infliximab + Aza: 1% anti-Infix antibodies

  20. Adalimumab in Moderate to Severe UC * • 8 week trial: Doses given weeks 0,2,6. • Primary endpoint: Clinical Remission (Mayo score < 2; no subscore >1). • * p=0.031 vs. placebo. • SAE: 7.6%, 3.8%, 4.0% respectively. 2 malignancies: both in placebo (basal cell; breast) Reinisch W et al. Gut ;2011 (online Jan 5, 2011: 10.1136/gut.2010.221127)

  21. Adalimumab: Induction of Clinical Remission in Moderate to Severe UC (DDW 2011) Week 8: Remission * p=0.019 vs. placebo. Clinical Remission • 8 week endpoint (52 week trial): Doses given weeks 0,2,6. • 494 Patients: moderate to severe UC • Primary endpoints: Clinical Remission at weeks 8 and 52. • Response rates: 34.6% placebo vs. 50.4% ADA (p<0.001) ABSTRACT ONLY Sandborn W et al. DDW 2011, abstract #744.

  22. Adalimumab: Mucosal Healing in Moderate to Severe UC (DDW 2011) Week 8 *p=0.032 Clinical Remission • 8 week endpoint (52 week trial): Doses given weeks 0,2,6. • 494 Patients: moderate to severe UC • Primary endpoints: Clinical Remission at weeks 8 and 52. ABSTRACT ONLY Sandborn W et al. DDW 2011, abstract #744.

  23. Back to the case: • Patient started on infliximab and azathioprine. • Initially also on topical therapies. • Steady response; steroids successfully tapered. • Subsequent colonoscopy revealed no active disease, although chronic mucosal changes and pseudopolyps characterized rectum – to –distal L colon.

  24. Case #2: Severe Crohn’s Disease • Dan Present

  25. New Patient Appointment • 30 yo W Male • 10- yr history of vague crampyabd pain, intermittent but became more persistent. • Recalls going to the local ER about 8 years ago while in college and subsequently having “intestine xrays where I had to drink barium” which suggested possible Crohn’s disease. Thinks he had a colonoscopy and “didn’t show anything” but didn’t know if the ileum was intubated.

  26. Current Symptoms • Post-prandial watery bowel movements. • Admits that he has lost about 20lbs in the past few months due to “it hurts when I eat too much.” • Fatigued. • Vague joint pains. • Asks if he can step outside to smoke a cigarrette…

  27. WHAT WOULD YOU DO? • Order a colonoscopy? • Order small bowel imaging? • If so, which one? • Start mesalamine 4g • Start metronidazole 500mg tid? • Start anti-TNF?

  28. Diagnostic Workup • SBFT: Multiple strictures of the distal jejunum, mid- and distal ileum, with normal intervening mucosa. Active inflammation. No proximal dilation. • Colonoscopy: colon normal; ileum: narrowed; some ulcerations. • Bx: Ileum: Ileitis c/w Crohn’s. Colon: normal • Diagnosed with “Crohn’s disease”

  29. Now, What Would YOU Do? • Mesalamine 4g • Budesonide CIR 9mg • Prednisone 40mg • 6MP initiation • Anti-TNF • Natalizumab • Surgery

  30. Clinical Course • Budesonide 9mg started • Plan is to decrease by 3mg every 3 weeks. • 6MP 75mg started (pt weight 75kg) • Increased to 100mg after 2-3 weeks. • (TPMT genotype was wildtype) • Although pt felt better on 9mg budesonide, he could not decrease the dose to 6mg without relapse

  31. At this point • WBC 3,500 Polys: 80%, Bands 2% • Hgb 12.5 • Platelet count: 200,000 • LFT’s: normal • 6TG: 325 6MMP 5,000

  32. What Would YOU Do? • Switch from budesonide to prednisone 40mg • 6MP dose increase • Anti-TNF • Natalizumab • Surgery

  33. You start an anti-TNF: • And stop the 6-MP? • And decrease dose of the 6-MP? • With same dose of 6-MP?

  34. Combination Therapy Increases Efficacy P<0.001 vs. aza P=0.022 vs. ifx P<0.001 vs. aza P=0.055 vs. ifx Columbel JF et al. N Engl J Med 2010;362:1383-95.

  35. Minimal Improvement • Is seen on the infliximab • Suspecting a need for surgery, you order at CT enterography: inflammation, • Still a substantial amount of SB activity, multiple strictures but none are obviously obstructive.

  36. What Would YOU Do? • Switch from budesonide to prednisone 40mg • 6MP dose increase • Switch Anti-TNF • Natalizumab • Surgery

  37. Decide to try Natalizumab • JC virus antibody status: negative • Patient stops 6MP • Starts natalizumab 300mg IV q 28 days • Able to slowly wean off of Entocort over 3 months • 6 months out: well on natalizumab

  38. Case 3: Severe Fistulous Crohn’s Disease • Russ Cohen and Dan Present

  39. Presentation To Your Office • 45 yo W M with fistulous Crohn’s disease to the perineal area for 10 years. • Colonoscopies to the ileum have always showed normal TI, normal colon, other than the distal rectum, which has some small ulcerations, and a anorectal stricture. • Now with increased fistula discharge and increased difficulty in passing BM

  40. Medications • Prednisone 25mg poqd • Mesalamine 4.8 g qd • Previously on short-term antibiotics • Had previous fistulotomy 6-years ago

  41. Physical Exam • Abdominal exam: all normal • Perianal exam- multiple draining perianal fistulas with mild fluctuance; previous fistula sites seen, as well as previous fistulotomy site. • Attempted rectal examination – stricture too tight to allow introduction of finger-tip.

  42. When do you call… The surgeon? • Trial of antibiotics first? • Trial of immunomodulators first? • Trial of anti-TNF first?

  43. When do you order… • Imaging? CT? MRI? Dynamic proctography? from: radiologyassistant.nl

  44. Start antibiotics, sent to surgeon • Orders MRI Pelvis to determine if fistulas connected to main cavity. • Examination under anesthesia • Dilation of the stricture (Hegar) • Flex sig to 25cm: only distal rectal disease. • Multiple fistulas emanating from a single fistula orifice on each side of the dentate line. • Fistulectomy x2, seton placed x2

  45. Patient now sits in front of you.. • With 2 setons coming out their bottom • Wanting to know, “What yagonna do?”

  46. What You Gonna Do? • Continue 5-ASA ? • Continue Steroids ? • Start antibiotics? • Start 6MP/ Azathioprine? • Start MTX? • Start anti-TNF? • Start natalizumab?

  47. What you did… • Patient started on azathioprine and infliximab. • Visits back to the surgeon after each induction dose of infliximab to evaluate need for setons (eventually removed). • Patient well on azathioprine and infliximab

  48. When do you stop therapy?

More Related